BTBioXcel Therapeutics, Inc. BTAI · NASDAQ
$0.07 -18.79% (-$0.02)
- Market cap
- $2.28M
- Enterprise value
- $93.9M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 3.1x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- 1,144.6%
- Gross margin
- 45.3%
- Net margin
- -9,549.9%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 0.29
- Free float
- 97.8%
About the company
BioXcel Therapeutics, Inc. (BTAI) is a biotechnology company that focuses on researching and developing new therapeutic approaches using artificial intelligence and data analysis. The company leverages advanced technologies and algorithms to identify and develop drugs for various diseases, including neurological and psychiatric disorders. With an innovative approach to drug development and treatment using artificial intelligence, the shares of BioXcel Therapeutics, Inc. (BTAI) may represent an intriguing investment opportunity for investors interested in biotechnology and medical research.
Sector
Healthcare
Industry
Biotechnology
CEO
Vimal D. Mehta
Employees
29
Headquarters
New Haven
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number